Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.030
Neutral
RSI(14)
34.012
Neutral
STOCH(KDJ)(9,3,3)
14.300
Oversold
ATR(14)
0.024
Low Volatility
CCI(14)
-118.083
Sell
Williams %R
90.387
Oversold
TRIX(12,20)
-1.203
Sell
StochRSI(14)
90.015
Buy
Search
MDxHealth SA
MDXHAdd to Watchlist
0.411USD
+0.011+2.70%
Close 07-30 16:00（ET）Quotes delayed by 15 min
21.11MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
+2.70%
5 Days
-2.68%
1 Month
+0.10%
6 Months
-88.26%
Year to Date
-88.49%
1 Year
-83.09%
Key Figures
0.400Open
0.418High
120.28KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.23%Turnover Ratio
0.400Prev. Close
0.400Low
30.32KTurnover
LossP/E Static
-1.04P/B
0.00%Div Yield TTM
-19.77%ROA
5.33052wk High
0.63Volume Ratio
-38.07MNet Profit
51.36MShares
-0.6509EPS TTM
0.56Beta
-2440.41%ROE
0.68052wk Low
4.60%Amplitude
56.05%Gross Margin
21.11MMarket Cap
-4.88Reward/Risk
4.32%Risk Rate
TradingKey Stock Score of MDxHealth SA
Currency: USD Updated: 2026-07-30Key Insights
MDxHealth SA's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 87 out of 384 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 2.80.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
MDxHealth SA's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
No data
MDxHealth SA Highlights
StrengthsRisks
MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 53.68% year-on-year.
Overvalued
The company’s latest PE is -0.63, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 25.38M shares, decreasing 1.08% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 63.68K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 1.09.
Analyst Rating
Based on
6
analysts
Strong Buy
Current Rating
6.040
Target Price
+325.35%
Upside Space
MDxHealth SA News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
6
analysts
Buy
Current Rating
2.800
Target Price
+569.86%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
MDxHealth SA
MDXH
6
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
0.409
Buy
MA10
0.417
Sell
MA20
0.438
Sell
MA50
0.538
Sell
MA100
1.441
Sell
MA200
2.579
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
MDxHealth SA Info
MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
Ticker SymbolMDXH
CompanyMDxHealth SA
CEOMr. Michael K. McGarrity
Websitehttps://mdxhealth.com/
Shareholders
Related Instruments
-4.49%
-3.63%
-1.11%
-2.15%
-0.44%
-0.26%
+0.03%
0.00%
-1.11%
-0.97%
+2.81%
-0.34%
-2.15%
-2.56%
-4.39%
+6.12%
0.00%
-1.09%
-2.76%
-0.88%Popular Instruments
FAQs
What is the current price of MDxHealth SA (MDXH)?
The current price of MDxHealth SA (MDXH) is 0.41.
What is the symbol of MDxHealth SA?
The ticker symbol of MDxHealth SA is MDXH.
What is the 52-week high of MDxHealth SA?
The 52-week high of MDxHealth SA is 5.33.
What is the 52-week low of MDxHealth SA?
The 52-week low of MDxHealth SA is 0.68.
What is the market capitalization of MDxHealth SA?
The market capitalization of MDxHealth SA is 21.11M.
Is MDxHealth SA (MDXH) currently rated as Buy, Hold, or Sell?
According to analysts, MDxHealth SA (MDXH) has an overall rating of Buy, with a price target of 2.80.
What is the Earnings Per Share (EPS TTM) of MDxHealth SA (MDXH)?
The Earnings Per Share (EPS TTM) of MDxHealth SA (MDXH) is -0.67.